Retroviral insertion site analysis following transplantation of marked hematopoietic stem cells (HSCs) is a powerful method for studying hematopoiesis in vivo. High-level gene transfer eciency was achieved in murine models in the late 1980s, but early human gene transfer protocols into hematopoietic stem and progenitor cells using the murine methodology showed consistently poor results. The utility of non-human primates as pre-clinical models has since become apparent. Modi®ca-tions in retroviral transduction conditions have resulted in stable long-term gene transfer eciency as high as 15 ± 20% to primitive repopulating cells in non-human primate models. This has permitted, for the ®rst time in a large animal model, tracking of individual stem and progenitor cell clones via insertion site analysis, an advantage over competitive transplantation studies, which cannot ®rmly evaluate the number or life span of individual clones contributing to hematopoiesis. Retroviral tracking studies in mice suggest that stable hematopoiesis may be dominated by a small number of clones, but these studies have been limited by insensitive detection methods, low numbers of transplanted stem cells, and limited life span of immunode®cient mice. Autologous transplantation studies in non-human primates have just begun and have the potential to shed light on controversial issues such as the number of clones contributing to stable hematopoiesis, clonal succession, and lineage commitment, as well as the eect of clinically relevant manipulations such as cytokines, chemotherapy, and radiation on hematopoiesis. TheseIntroduction Gene marking protocols designed to track the fate of transduced cells, without therapeutic intent, were the ®rst clinical gene transfer studies carried out in humans. The work by Rosenberg et al. (1990) determining the fate of tumor in®ltrating lymphocytes using retroviral gene transduction ®rst demonstrated the feasibility and safety of human gene marking studies. Gene marking could theoretically be used to track the in vivo behavior of almost any cell type, but in practice it has been applied primarily to investigate whether malignant cells contaminate human hematopoietic stem cell (HSC) grafts, and in basic research laboratories it has been used to study the in vivo behavior of HSCs and their progeny (Brenner et al., 1993; Brenner, 1996; Guenechea et al., 2001) .
The potential importance of non-human primate models for gene transfer research was recognized even before the initial human clinical trials (Anderson et al., 1986; Kanto et al., 1987) , but it was the disappointing results of the early human studies that uncovered the poor performance of murine and in vitro human progenitor cell assays to predict in vivo results in humans, refocusing interest on non-human primate models (Brenner, 1996; Dunbar, 1996) . Even for more basic research investigations of hematopoiesis, it also became clear that animals with life spans and hematopoietic demands more similar to humans would be important for understanding in vivo kinetics and control of blood cell production (Abkowitz et al., 1996) . In early marking studies in humans and other large animals, the level of marked cells in peripheral blood was consistently less than 1%, and this precluded the use of retroviral insertion site analysis as formal proof of stem cell transduction, or for detailed investigations of in vivo hematopoiesis via tracking of progenitor and stem cell marked clones, approaches that had been successful in murine models. However, over the past several years, retroviral transduction of non-human primate repopulating cells has signi®cantly improved, allowing tracking of multiple individual stem cell clones in this large animal model. Such approaches may oer critical insights in the future regarding stem cell plasticity and other exciting current biologic questions with direct clinical importance (Lemischka, 1999; Lagasse et al., 2000; Orlic et al., 2001a,b) .
Models for investigating hematopoiesis and gene transfer
Despite enormous progress toward the characterization of human hematopoietic stem cells via cell surface phenotype, cycling characteristics, or functional properties such as dye eux, there is no in vitro surrogate assay that can identify a true human hematopoietic stem cell, de®ned as a single cell able to both self-renew and dierentiate into all hematopoietic lineages. Critical characteristics such as homing to the marrow microenvironment are also dicult to model in vitro. The drawbacks of relying on in vitro assays of primitive human hematopoietic cells as surrogates for optimization of gene transfer strategies or investigation of stem cell behavior became obvious when results from early clinical gene transfer trials demonstrated that high level gene transfer into colony forming units (CFUs) or even long-term culture-initiating cells (LTCICs) did not predict successful transduction of repopulating cells, and that committed progenitors appeared not to contribute to reconstitution in vivo Hanania et al., 1996) .
It has been possible during the last decade for many laboratories to achieve HSC retroviral gene transfer in close to 100% of recipient mice, with mean proviral copy numbers of 0.1 ± 0.5 vector copies per cell. This has allowed correction of genetic defects in mutant mice, and permitted investigation of hematopoiesis using insertion site analysis (see below) Karlsson, 1991; Bunting et al., 1998) . Factors important in achieving high eciency gene transfer to murine HSC include treatment of the donor animals with 5-¯uouracil to induce cycling of primitive precursors in the bone marrow (Bodine et al., 1991; Harrison and Lerner, 1991) , vectors with a titer of 10 5 or greater, and transduction performed in the presence of multiple cytokines usually including IL-3 and/or IL-6 with stem cell factor (SCF) (Luskey et al., 1992) and more recently Flt-3 ligand (FLT) (Petzer et al., 1996) . However, the application of these principles in human clinical trials did not result in the same high gene transfer eciency, and thus alternative models for preclinical gene therapy optimization and for in vivo analysis of hematopoiesis have been sought Dunbar, 1996) .
The de®nitive assay for mouse hematopoietic stem cell activity is repopulation of irradiated or stem cellde®cient W/W v mice with transplanted hematopoietic cells. It is not possible to design the same type of assay in a human transplantation model. Alternatively, investigators have developed xenograft models involving transplantation of primitive human hematopoietic cells into immunode®cient animal recipients in order to study the behavior of engrafting human hematopoietic cells. The two major approaches use either genetically immunode®cient mice or immunologically-naive fetal sheep as recipients (Larochelle et al., 1996; Zanjani et al., 1996) . Primitive human bone marrow or cord blood cells will engraft fetal sheep at low levels, and at least 50% will have long-term persistence of human cells, with secondary or even tertiary transplantation into additional fetal sheep possible (Zanjani et al., 1996) . Unfortunately, this model is technically challenging and not practical for most research groups. It is also possible that homing and engraftment in the fetal and trans-species environment does not accurately re¯ect hematopoiesis in an adult human.
Murine xenotransplant models have been developed using several alternative immunode®cient mouse strains. BNX mice are almost completely immunode®-cient due to being homozygous for three mutations leading to natural killer cell de®ciency (bg mutation), lack of thymus (nu mutation) and loss of some B-cell function (xid mutation). Long-term engraftment with human myeloid and T cells can be demonstrated, however high level engraftment requires cotransplantation of stromal cells expressing human IL-3, and B cell development has not been achieved in this model (Nolta et al., 1994) . SCID mice lack functional T and B-lymphocytes and the NOD strain of mice, which is susceptible to diabetes, is NK cell de®cient. The crossed strain, NOD ± SCID, is severely immunode®-cient and a number of groups have shown it to be a better host for human hematopoietic cells than SCID mice (Greiner et al., 1998) . High-level engraftment is possible, especially with cord blood cells, and limiting dilution assays to quantitate primitive human engrafting cells are feasible (Cashman et al., 1997) . The majority of maturing human cells in this model are B lineage cells, and modi®cations such as implantation of human fetal bone or thymus, and/or use of transgenic strains engineered to express human cytokines have improved engraftment levels with human myeloid cells and/or the T lymphoid lineage (Bock et al., 1995) . This model has been used to identify a pluripotent stem cell, termed SCID-repopulating cell (SRC) that is more primitive and clearly distinct from prior multipotent primitive human hematopoietic cell populations identi®ed using in vitro methodology (Larochelle et al., 1996) .
The major problem with xenograft assays is that human hematopoietic stem cell properties such as homing, engraftment, proliferation and dierentiation in these models might be very dierent from endogenous in vivo human hematopoiesis. Quantitation of stem cell numbers may be greatly underestimated due to inecient homing. The life-span of immunode®cient mice is signi®cantly shortened by their susceptibility to lymphoma, and therefore following engrafted human cells for more than 6 ± 12 weeks requires retransplantation into a second recipient mouse, further compounding the impact of homing de®ciencies, and making long-term follow-up of steady-state hematopoiesis impossible. Engraftment of adult human marrow or mobilized peripheral blood SRC is almost two logs less ecient than engraftment of cord blood cells; therefore most studies utilizing this model have been carried out using cord blood, with unclear relevance to other stem cell sources.
Non-human primate models
Mice dier from humans in many regards, speci®cally in hematopoietic demand and stem cell turnover, retroviral receptor expression levels, and patterns of fetal, adult, and stress hematopoiesis (Orlic et al., 1996; Abkowitz et al., 2000) . Many hematopoietic cytokines show limited homology or cross-reactivity between human and mice. Large animals such as dogs or nonhuman primates are genetically more closely related. Phylogenetically, the great apes such as chimpanzees are most closely related to humans, but using them for research purposes is not practical (Van Beusechem and Valerio, 1996) . Small and abundant Old World macaques such as rhesus have cells that respond to human cytokines and can be stained with anti-human antibodies to hematopoietic cell surface molecules such as CD34 (Berenson et al., 1988; Burger et al., 1990) . There is an extensive literature over several decades regarding stem cell transplantation and radiation sensitivity in rhesus macaques and baboons (van Bekkum, 1978) . Since primates are not inbred, results are more likely to be universally applicable than those obtained using one mouse strain.
Studies utilizing non-human primates are expensive and technically-challenging, due to the purchase costs of the animals and the sophisticated training and resources required to support large animals through ablative radiation or chemotherapy. Only a handful of research groups worldwide have the facilities for these procedures. Most experiments cannot be performed with animal numbers allowing statistical power approaching the usual standards for murine models or in vitro assays. Instead, the use of internal controls, via a competitive repopulation experimental design, can yield more information with feasible animal numbers Kiem et al., 1997) .
Results from early clinical trials were very similar to data obtained in non-human primates using similar vectors and transduction conditions, suggesting that Old World monkeys such as macaques and baboons would be reliable pre-clinical models for human gene transfer studies. The use of conditions found to produce much more ecient gene transfer to repopulating cells in non-human primates (see below) has now resulted in the ®rst unequivocal successful human gene therapy protocol in children with X-linked SCID, validating the utility of non-human primate models (Cavazzana-Calvo et al., 2000) . A recent review can be consulted for more detail regarding use of these models for transplantation and gene therapy research, but important concepts will be summarized below .
Results of gene transfer to HSCs in non-human primates
Murine retroviruses based on the Moloney murine leukemia virus (Mo-MLV) were the ®rst and still are the most widely used vectors in gene transfer studies (Miller, 1992) . They are the only vector system that has thus far been used to transduce human hematopoietic stem or progenitor cells in a clinical trial. They stably integrate into the genome of the marked cell so the transduced cell can be followed for its entire life span and also for the lifespan of progeny cells. This property has been invaluable for tracking clonal contributions to hematopoiesis in both mice and primates as described below. By the early 1990s, reports of successful gene transfer to murine HSC led to the application of similar retroviral transduction protocols in non-human primate experiments. Unfortunately, results from the ®rst 5 years were very disappointing, with long-term marking levels at the limit of detection, even by PCR, and thus clearly inadequate for future clinical applications in humans or for detailed analysis of in vivo hematopoiesis (Van Beusechem and Valerio, 1996) . These studies utilized steady-state bone marrow as a target cell source and generally included the cytokines IL-3, IL-6, and SCF during the transduction period, either in the presence of the vector producer cell line or ®ltered vector supernatant.
In primate models, the combination of SCF plus G-CSF results in superior mobilization of primitive hematopoietic cells compared to G-CSF alone (Andrews et al., 1995) . By using a reduced volume leukapheresis, ecient collections of large number of mobilized peripheral blood cells became possible . As in humans, use of this HSC source decreased the time to engraftment and need for transfusion support after transplantation, and improved overall survival of animals taken through ablative autologous transplantation procedures. Targeting mobilized peripheral blood or marrow collected after SCF and GCSF administration also appeared to improve gene transfer eciency compared to steadystate marrow, potentially by increasing expression of amphotropic retroviral receptors, or improving competition with endogenous HSCs (Bodine et al., 1994; Dunbar et al., 1996) .
Studies attempting to expand murine or human HSCs ex vivo have generally shown maintenance or loss of in vivo long term repopulating ability, despite marked increases in total cell number, CD34+ cell number, committed progenitors and even SCIDrepopulating cells (Emerson, 1996; Srour et al., 1999) . This issue was investigated in the rhesus autologous transplantation model, using retroviral marking to follow the in vivo fate of the cultured cells. G-CSF+SCF mobilized peripheral blood CD34+ cells were cultured in the presence of multiple cytokine combinations, with or without autologous stromal monolayers, and transduced with two distinguishable vectors carrying the neomycin resistance gene. For each animal, one cell aliquot was then cryopreserved, and the second aliquot was`expanded' ex vivo for an additional 6 ± 10 days. Despite many-fold higher numbers of total cells and CFU from the expanded aliquot of marked cells, both short and long term in vivo marking was almost exclusively derived from nonexpanded transduced cells (Tisdale et al., 1998) . This re¯ects a loss in reconstituting ability of transduced cells with increased duration of culture, and has also been observed in NOD/SCID studies (Dorrell et al., 2000) .
However, these rhesus experiments were a breakthrough, because for the ®rst time in vivo marking was found to have increased markedly, to 5 ± 20%, simply by the inclusion of FLT and autologous stroma along with the IL-3, IL-6 and SCF during the initial brief transduction period. Concurrently, high level marking was reported in the baboon model using a GALVpseudotyped retroviral vector with transduction performed in the presence of SCF, FLT, IL-6, megakaryocyte growth and development factor (MGDF), and the CH-296 fragment of ®bronectin (RetroNectin) (Kiem et al., 1998) . The extracellular matrix protein ®bronectin and in particular its carboxy-terminal fragment, CH-296, has been shown to increase retroviral transduction eciency due to co-localization of murine retroviral vectors and primitive target cells , and/or improving ex vivo survival of stem cells (Yokota et al., 1998) . We have also observed that RetroNectin can replace stromal support during transduction, and have now followed animals with stable marking levels of 5 ± 15% in both lymphoid and myeloid circulating cells for up to 3 years post-transplantation .
Recently, we have used gene marking to further investigate the in vivo behavior of cultured and manipulated primitive repopulating cells. Murine and xenograft models suggested that actively-cycling stem cells have an engraftment defect compared to cells that are quiescent at the time of transplantation (Gothot et al., 1998; Habibian et al., 1998) . SCF+G-CSF mobilized CD34+ cells that were transduced with retroviral vectors in the presence of SCF/FLT/MGDF on RetroNectin and then continued in culture without transduction for 2 more days in the presence of nonstimulatory culture conditions resulted in signi®cantly higher levels of engraftment with marked cells compared to cells infused immediately after 4 days of culture and transduction in the presence of stimulatory cytokine combinations. We hypothesize that this improvement in gene transfer might be due to avoidance of active cell cycling at the time of reinfusion (Habibian et al., 1998; Takatoku et al., 2001) .
Alternative vector pseudotypes and alternative vectors
Pseudotyping vector particles with alternative envelope proteins can be an eective method to change target cell speci®city and increase transduction eciency, if receptor density is a limiting factor. The amphotropic receptor appears to be present at very low density on murine HSCs, and direct comparison has demonstrated that this factor accounts for low murine HSC transduction eciency using amphotropic as compared to ecotropic vectors (Orlic et al., 1996) . This receptor also appears to be rare on human and macaque CD34+/CD387 cells. Pseudotyping standard retroviral vectors with alternative envelope proteins has been explored in non-human primate models. The gibbon ape leukemia virus (GALV) envelope improved the transduction eciency of engrafting hematopoietic cells in the baboon (Kiem et al., 1997) . Pseudotyping with the vesicular stomatitis G protein (VSV-G) is also being attempted because this envelope interacts with ubiquitous cell membrane phospholipids, however there is little comparative data to date except in the xenograft model (Rebel et al., 1998) . Retroviral vectors pseudotyped with the feline endogenous retrovirus (RD114) envelope are very promising in the NOD/SCID model, and preliminary data in non-human primates is encouraging (Kelly et al., 2001 ).
One of the major disadvantages of retroviruses is that they transduce only actively dividing cells, since entry into the nucleus prior to integration is dependent on the breakdown of the nuclear membrane during M phase. HIV-1 derived lentiviral vectors have been developed and studied in vitro and in vivo. Their great advantage is that they can transduce at least some types of noncycling quiescent cells (Naldini, 1998) . Generally the VSV-G envelope has been used to pseudotype lentiviral vectors, since entry via CD4, the native HIV envelope receptor, is not useful for targets other than T cells. Using a lentiviral vector encoding GFP, low level (*1%) multilineage marking has been demonstrated in the rhesus model even with only a short ex vivo culture period and in the absence of stimulatory cytokines . Further optimization and safety studies are required before widespread use of lentiviral vectors in human clinical trials, since to date the results in primate models are inferior to standard retroviral vectors, although results in xenograft models are quite encouraging (Miyoshi et al., 1999) .
Analysis of in vivo hematopoiesis
There are two approaches that have been used to study the kinetics and lineage contributions of hematopoietic stem cells in vivo. The ®rst involves analysis of the relative contributions of progeny cells containing or expressing variant alleles of a polymorphic gene. In females heterozygous for common X-linked polymorphic alleles, such as the glucose-6-phosphate dehydrogenase gene or the androgen receptor, the process of lyonization early in fetal development results in approximately 50% of hematopoietic progeny cells expressing one allele or the other when hematopoiesis is polyclonal (Fialkow et al., 1977) . The number of stem cell clones contributing to hematopoiesis or to speci®c lineages can be assessed mathematically by analysing the variance in the contributions of one allele versus the other over time. Detection of either fully monoclonal or oligoclonal hematopoiesis is possible, but the degree of polyclonality (i.e. 10 clones versus 10 000 clones) is dicult to quantitate, and the fates of individual stem or progenitor cell clones are impossible to follow. This technique can be used in either steadystate heterozygous female humans or animals, or after transplantation of female donor stem cells into a male recipient.
A variant of this population-based analysis that has been utilized in the mouse involves transplantation of a mixture of stem cells from congenic donors homozygous for either of the two alleles of a gene such as CD45 (Ly5 in the mouse) or beta hemoglobin. The proportion of hematopoietic progeny derived from each allele is subsequently monitored (Harrison et al., 1988) . Criticism of this method is that, in the absence of limiting dilution analysis, studies are limited to evaluating kinetics of large populations of stem cells rather than individual stem cell clones.
The second general approach utilizes retrovirallytransduced hematopoietic stem or progenitor cells. When a retroviral vector integrates, in the absence of helper virus, the proviral insert is completely stable within the host cell genome, and is passed on without modi®cation to every daughter cell. Integration is random, and thus the unique retroviral integration site can be identi®ed and serve as a clonal tag for a stem or progenitor cell and all of its progeny, allowing subsequent monitoring of the life-span and lineage contributions derived from an original transduced primitive cell (Capel et al., 1989) . One criticism of this method is that, although stem cells predominantly reside in the G 0 stage of the cell cycle, only cycling cells can be eciently transduced with standard murine leukemia virus-derived retroviral vectors, and the ex vivo culture period required to allow transduction could alter normal stem cell behavior. A related approach that avoids a requirement for cell cycling is to mark cells with unique chromosomal aberrations via radiation exposure. This marking method can be criticized because the radiation damage may alter normal stem cell behavior in addition to causing large detectable chromosomal aberrations.
Each general approach had yielded important and complementary insights into the properties of hematopoiesis. Predictions regarding stem cell numbers or behavior initially based on one approach can be validated by use of the other. It is generally agreed upon that short-lived neutrophils or less optimally red blood cells, rather than lymphocytes, must be assessed by either approach to assess ongoing hematopoiesis, since both T and B lymphocytes may have long half-lives and not re¯ect production from stem or progenitor cells. Insertion site studies rely on syngeneic or autologous transplantation, as are many studies using allelic variance analysis, since endogenous hematopoiesis is too polyclonal to permit informative analysis, and therefore limiting dilution transplantation series are performed to reach a threshold of detectable variance. This may be misleading if normal steady-state hematopoiesis is markedly dierent from the post-transplantation setting, and increases the importance of very longterm follow-up post-transplantation in order to reach a new steady-state.
Population-based studies
Murine, feline, and human allelic polymorphisms suitable for analysis of hematopoiesis have been identi®ed. Murine competitive repopulation experiments use limiting dilutions of a test stem cell population (i.e. bone marrow), homozygous for one allele, mixed with a ®xed dose of congenic cells homozygous for the alternative allele (Harrison, 1980) . The prevalence of the two alleles can then be followed in T and B lymphocytes, granulocytes, platelets, and erythrocytes. Limiting dilution to the point where, theoretically, transplantation of a single stem cell occurred resulted in regeneration of multilineage long-term hematopoiesis (Boggs et al., 1982; Harrison et al., 1988) . Steady-state hematopoiesis was predicted to be polyclonal when non-limiting dilution transplants using mixtures of congenic marrow were performed, although with serial transplants, stem cell exhaustion appeared to occur, and oligoclonal hematopoiesis developed in subsequent recipients or with the use of aged marrow donors (Harrison et al., 1988) . Analysis of variance in a competitive repopulation model using Poisson statistics inferred the existence of short-term versus long-term repopulating cells, and suggested a time interval of up to 14 ± 32 weeks posttransplantation contributed by short-term repopulating cells in the mouse (Zhong et al., 1996) . This elucidated the importance of following hematopoietic contributions in mice for at least 4 ± 6 months to make any conclusions about stable long-term hematopoiesis.
This same competitive repopulation approach was utilized to generate data that could be used for computer modeling to estimate stem cell frequency and rates of replication, dierentiation, and apoptosis. Frequency and replication rates for mouse hematopoietic stem cells were predicted to be 8 per 10 5 nucleated marrow cells and 1 per 2.5 weeks, respectively (Abkowitz et al., 2000) . The computer model assumes that individual stem cells act independently, the fate of a HSC is determined randomly and not via extrinsic in¯uences, and all stem cell clones contribute equally to hematopoiesis at a given point in time. The allelic variance analysis does not allow determination of whether these assumptions are correct, however the direct analysis of stem cell clones via insertion site analysis could provide further insight into these issues.
A similar approach has been used in one large animal model. Female Safari cats heterozygous at the G6PD locus were used as marrow donors for transplantation into fully myeloablated recipients, initially at very low marrow cell doses in hopes that analysis of variance could be informative for mathematical modeling of stem cell numbers and behaviors (Abkowitz et al., 1992 (Abkowitz et al., , 1996 . The ratio of the two G6PD alleles in colony progenitors (BFU-E and CFU-GM) was measured following transplantation. Several conclusions were drawn from these studies. In contrast to the mouse, the frequency of cat HSCs is only 6 per 10 7 nucleated marrow cells and their replication rate 1 per 8.3 ± 10 weeks. Since this data suggests that HSC are less frequent and divide more slowly in larger animals, yet larger animals have a longer lifetime and larger blood volume, another implication is that the proliferative capacity of HSCs (number of dierentiated progeny produced per HSC) is higher in larger animals. Non-human primates and humans are predicted to be very similar to cats, based on hematopoietic demand, turnover, and size. Baseline hematopoiesis in nontransplanted young Safari cats is balanced (CFU-GM and BFU-E showed approximately equal proportions of each G6PD phenotype) and stable (no change in proportions over time), suggesting overall polyclonal hematopoiesis. In contrast, the ratios in transplanted cats¯uctuated throughout the initial 1 ± 1.5 year post-transplant observation period, with some cats skewing towards a single G6PD phenotype.
At this time point, the authors concluded that their data ®t with the theory that hematopoiesis derives from clonal succession (Kay, 1965) , and not with the primary alternative theory, that individual original stem cells and their progeny contribute inde®nitely to hematopoiesis. To elaborate, the theory of clonal succession hypothesizes that hematopoiesis derives from a periodically changing subset of active stem cells. Stem cells are active for a discrete lifetime or time period, self-renewing into progeny cells that eventually apoptose or inactivate, and hematopoietic output is replaced sequentially by other stem cells activated from a stem cell reserve.
Another interpretation of the data is possible, however, if one hypothesizes that, as in the mouse, the cat has short-term and long-term repopulating cells. Given the slower replication rate of cat hematopoietic stem cells, it may be that the 1 ± 1.5 years of observation is still within the time period where short-term repopulating cells are active or, when limiting numbers of stem cells are transplanted, that large variations occur simply from stochastic changes. This possibility was con®rmed by their subsequent 6-year follow-up study (Abkowitz et al., 1995) , where they found that the period of clonal¯uctuations in cats extended to 1 ± 4.5 years, and that after that time, in some animals, a single G6PD phenotype predominated. This later result does not support a theory of clonal succession and instead suggested that once the period of clonal¯uctuation ends, monoclonal or oligoclonal hematopoiesis predominates and can be stable based on an inde®nitely active population of stem cells.
The X-chromosome inactivation phenomenon has also been utilized to study clonality in humans. Initially, expression of G6PD A versus B alleles was studied in rare human heterozygous females, primarily to establish whether myeloproliferative disorders such as chronic myelogenous leukemia or polycythemia vera were clonal (Fialkow et al., 1977) . More recently, a number of much more frequent X-linked polymorphisms have been analysed via methodology based on PCR ampli®cation followed by methylation-sensitive restriction enzyme digestion to distinguish the active versus inactive alleles. The human androgen receptor gene (HUMARA) is the favored locus, since heterozygosity of short tandem repeat (STR) alleles within this locus is close to 90% in Caucasian females, while other earlier studies used the phosphoglycerate kinase gene (PGK), where heterozygosity is around 30%.
Such studies have shown a number of interesting ®ndings. Skewing increases with age even in nontransplanted individuals. A skewing ratio of 43 : 1 was seen in 38 ± 56% of normal females over 60 years of age (Busque et al., 1996; Champion et al., 1997; Gale et al., 1997; Tonon et al., 1998) . This ®nding could indicate eventual stem cell exhaustion, or alternatively, an advantage for one allele versus the other. Skewing does not appear to predispose toward malignant clonal hematopoiesis, as women with skewed X-inactivation in their granulocytes have been followed for several years with no evidence of progression to a hematological disease; therefore it seems unlikely that all of the skewing in older patients is due to incipient myelodysplasia (Tonon et al., 1998) . Instead, there is evidence from the Safari cat that certain X chromosome polymorphisms may be linked to a locus that in some way provides a competitive advantage to cells expressing one parental X-chromosome over the other (Abkowitz et al., 1998; Brown and Robinson, 2000; Christensen et al., 2000) . This issue complicates very long term analysis of hematopoiesis based on these polymorphisms, if stem cell behavior is not necessarily independent of the active versus inactive X-chromosome.
Allogeneic bone marrow transplant recipients typically have a balanced pattern of X-chromosome inactivation (Nash et al., 1988) . Based on the data in cats, this suggests that, even though only a fraction of a donor's stem cells are transplanted, the standard dose results in stable polyclonal hematopoiesis, however, contributions of individual stem cell clones in humans can not be followed using this methodology.
Studies utilizing retroviral insertion site analysis
Retroviral insertion analysis for clonal tracking has been carried out in mouse transplantation models since the early 1980s (Dick et al., 1985; Keller et al., 1985) . In these studies, retroviral insertion sites were monitored via Southern blot analysis of insertion-site speci®c bands in DNA from the four major peripheral blood cell lineages (Lemischka et al., 1986; Snodgrass and Keller, 1987; Keller and Snodgrass, 1990) . One study carried out evaluations at 6 ± 8 week intervals over as long as a 16-month time period, with 142 unique retroviral integration sites analysed in 63 reconstituted animals . The 4 ± 6 month period post-transplant was notable for marked changes in clonal contributions. Some clones contributed only transiently in the beginning of this period, while others began contributing later. Upon retransplantation of bone marrow to secondary recipients, previously undetected retroviral insertion site bands appeared. Some clones, however, were present during the entire post-transplant period. After 6 months, a relatively small number of clones were detected. The majority of these clones were present at all times monitored after 6 months. The detected clones were present in all lineages.
Based on statistical modeling, the clonal variability seen in the ®rst 4 ± 6 months was consistent with a stochastic process where the transplanted stem cells have randomly determined fates of self-renewal versus dierentiation. Due to the small numbers of initial progeny, a single clone may result in variable lineage contribution early after transplantation depending on the random impact of the ®rst several cell division events, or even proceed to extinction due to a higher rate of dierentiation compared to renewal. After a stem cell clone expands due to self-renewal, however, the law of averages would predict that the clone would eventually have stable and equal contributions to all lineages.
Although the stem cell decision to self-renew vs dierentiate appears to be stochastic, the particular lineage into which a stem cell dierentiates may not be randomly determined . There are several pieces of evidence for this. Pluripotent stem cells were sometimes seen to contribute to a myeloid lineage prior to a lymphoid lineage, but never the reverse. This may also have been due to the much longer half-life of lymphoid versus myeloid cells. Some pluripotent stem cells were observed to stop contributing to the monocyte ± macrophage lineage, but to continue contributions to the granulocyte and lymphoid lineages. However, all these studies were limited by the very insensitive detection method used, namely Southern blot analysis, with each clone needing to make up at least 5% of a lineage in order to be identi®ed. Given that overall marking levels were rarely greater than 20 ± 50%, this issue was compounded, and no more than 3 ± 4 clones were ever detected at individual time points.
These studies also con®rmed the limiting-dilution studies inferring the existence of short-term versus long-term repopulating cells. They also suggested that, after 6 months, reconstituted hematopoiesis might be oligoclonal, with a small number of clones contributing stably and continuously to all lineages. This theory is in contrast to the theory of clonal succession, where hematopoiesis is derived from sequential short-lived clones with limited-self renewal ability. Whether these studies pertain to baseline hematopoiesis, where the starting stem cell number is presumably much larger, is still unclear. The methodology used to culture and transduce the cells ex vivo also probably resulted in marked depletion of reconstituting stem cells, since coculture on producer cell lines was performed with IL-3 as the lone supportive cytokine added during transduction. Therefore, the oligoclonal or monoclonal hematopoiesis that resulted, and the early marked uctuations may have been due to a low number of infused viable stem cells.
Furthermore, another group has performed sequential retroviral insertion site analyses in the mouse with results more consistent with the theory of clonal succession (Drize et al., 1996 (Drize et al., , 2001 . With repeated bone marrow sampling every 1 ± 3 months over 12 ± 14 months, they saw only one out of 12 mice that had oligoclonal hematopoiesis. The remainder of the mice exhibited patterns consistent with polyclonal hematopoiesis. This result, which is contrary to previous studies, may be explained by the fact that this study had greater sensitivity to detect small clones due to the use of PCR in addition to Southern blot analysis. A caveat to this study is that the technique used for detection of retroviral integration sites was to serially sample bone marrow from recipient mice and inject aliquots into secondary irradiated recipients, with subsequent PCR analysis of CFU-S (splenic colonies from these mice sacri®ced 10 days after transplantation). This technique may be¯awed, however, because of the resulting small sample size for clonal analysis, and, as already discussed, the considerable clonal uctuation immediately following transplantation. Furthermore, when this group performed clonal tracking in a group of mice with unique chromosomal aberrations induced by sublethal irradiation, about 10% of clones were found to be present during the entire 14-month time period monitored.
The studies discussed up to this point have been carried out with mouse stem cells transplanted into other mice. Recently, studies have also been published regarding the transplantation of human cells into immunode®cient mice, with periodic sampling of bone marrow for retroviral integration site analysis by PCR and/or Southern blot (Guenechea et al., 2001) . Due to the limitations of NOD ± SCID lifespan, clonal tracking in this study was only carried out for a period of 12 weeks, but the results were similar to previous congenic mouse studies at this time point, with signi®cant clonal variability seen. In another study, BNX mice were analysed 7 ± 10 months following transplantation, past the point where stable oligoclonality arose in previous congenic mice experiments (Nolta et al., 1996) . Only three out of 24 mice, however, had a common integration site in myeloid and lymphoid lineages. These results suggest that (1) either the period of clonal uctuation in humans is longer than in mice, which would not be a surprise given the cat data discussed previously, or (2) the clonal succession theory must be considered. It is also possible that the lymphoid cells being analysed were very long-lived progeny of infused lymphoid precursor cells or derived from multipotent clones active only early after transplantation.
Tracking of stem and progenitor cell clones in the non-human primate model Achievement of high level, stable in vivo retroviral marking after transplantation of transduced CD34+ peripheral blood cells in the rhesus macaque autologous transplantation model has allowed our group to perform a detailed analysis of clonal contributions to hematopoiesis in a large animal . Initially two animals were studied. Each received a high transplant dose of CD34+ cells (7 ± 21 million per kg). In contrast to previous studies in cats or xenografted immunode®cient mice, this high dose of cells resulted in more physiologic post-transplantation hematopoiesis. Stable marking levels of 0.05 ± 0.10 genomes/cell in peripheral blood mononuclear cells and granulocytes were measured by Southern blot and PCR analysis (corresponding to 5 ± 10% of cells containing vector, assuming one copy per cell).
We initially utilized the inverse PCR technique to identify vector insertion sites, and thus progeny of individual progenitor or stem cell clones (Nolta et al., 1996; Ochman et al., 1988) . Figure 1 summarizes this approach. The technique has several limitations. When DNA containing multiple dierent insertions is analysed, the variable eciency of the circularization step results in only a few favored insertion bands being ampli®ed, not corresponding to the relative contribution of the clone to a cell population. Therefore, we found that analysis of individual marrow CFU post-transplantation was the only feasible approach to survey the diversity of clones present. Even in CFU known to be positive for vector, only 30% had successful inverse PCR identi®cation of the insertion site. Despite these technical caveats, the initial analysis was very interesting. During the ®rst 24 months post-transplantation, over 50 dierent insertion sites and therefore clones were identi®ed in each animal . Only rare CFUs had more than one inserted provirus, con®rming the close correlation between copy number assessed by Southern blot and analysis of individual CFU. In several instances, common integration sequences were found in both myeloid CFU and T and/or B cell populations, and in both myeloid CFU and erythroid burst forming units (BFU-E). These data indicate that at least 50 dierent primitive precursors were transduced and able to contribute to in vivo hematopoiesis over time in both animals, with some clones contributing early after engraftment still detected up to 24 months later (unpublished data). Reliance on sampling of individual CFU in the presence of highly polyclonal hematopoiesis made tracking of individual clones dicult.
In collaboration with Dr Christof von Kalle, the clonal contributions to hematopoiesis have been studied using a much more robust technique termed ligation-mediated PCR (LAM ± PCR). This method permits detection of highly polyclonal insertion sites in DNA from cell populations. The LAM ± PCR methodology is extremely sensitive, able to identify insertion sites at a single cell level in a background of non-vector-containing or polyclonal DNA. This sensitivity is based on a modi®cation of a published technique utilizing extension primer tag selection, ligation of a linker following restriction enzyme digestion, and solid-phase nested PCR (Schmidt et al., 2001) . In contrast to inverse PCR, LAM ± PCR permits simultaneous identi®cation of individual insertion clones in a highly polyclonal population of cells, such as peripheral blood granulocytes. Analysis of granulocyte DNA 6 months post-transplantation identi®ed over 80 distinct clones, similar to the number of clones identi®ed by inverse PCR, but with LAM ± PCR they were all demonstrated to be contributing at a single time point (Schmidt et al., manuscript submitted) . Calculations based on overall marking levels results in an estimate of 800 ± 1000 active repopulating stem cell clones. Based on the original cell dose infused, this allows an estimate of the frequency of repopulating cells in mobilized blood of approximately one in 40 million (or one in 400 000 CD34-enriched cells).
We have begun to ask a number of questions regarding hematopoiesis in this model. Conventional PCR primers were designed to track speci®c clones over time and in dierent lineages. Clones initially identi®ed from granulocytes at 6 months post-transplantation began to contribute as early as 6 weeks post-transplantation, and have persisted for up to 3 years post-transplantation. Thus far we have no evidence for exhaustion of speci®c clones. 2/3 clones identi®ed in granulocytes at 6 months post-transplantation also contributed to B and T lineages. Thus far we have not analysed lymphoid clones to ask whether a majority of these clones also contribute to myelopoiesis. We plan to follow unperturbed animals for their life span to answer questions regarding clonal succession and lineage commitment. We will also be able to Figure 1 Inverse PCR technique for insertion site analysis assess the impact of clinically relevant manipulations such as cytokines, chemotherapy or radiation on the number and identity of contributing clones. Lastly, this type of analysis will be critical to gain insights into the observations of presumed stem cell`plasticity', in terms of asking whether or not the exact same cell can produce both hematopoietic and non-hematopoietic tissues.
